PTPN1-related autoinflammation is a common cause of Aicardi-Goutieres syndrome with reduced penetrance

This study identifies *PTPN1* variants as a significant cause of Aicardi-Goutières syndrome, particularly characterized by later onset and reduced penetrance, while also linking these variants to a broader spectrum of autoinflammatory and autoimmune phenotypes.

The Gist

The Big Picture: A Broken "Off Switch"

Imagine your body's immune system is like a high-tech security team. Its job is to fight off viruses and bacteria. Usually, when the alarm goes off (a virus is detected), the security team rushes in, fights the bad guys, and then stops. They have a built-in "off switch" to prevent them from attacking your own body once the danger is gone.

This paper is about a specific gene called PTPN1. Think of PTPN1 as the master "Off Switch" for that immune security team.

In this study, researchers found that when this "Off Switch" is broken (due to a genetic mutation), the security team gets confused. It keeps sounding the alarm and attacking even when there is no virus. This causes the body to turn against itself, leading to a condition called Aicardi-Goutières Syndrome (AGS).

What is Aicardi-Goutières Syndrome (AGS)?

AGS is a rare, serious condition where the body's immune system attacks the brain and spinal cord. It's like a security team that decides the building itself is the enemy. This causes:

• Brain inflammation: Leading to developmental delays, loss of skills (like walking or talking), and seizures.
• Calcium deposits: Tiny bits of calcium build up in the brain (like rust on a pipe).
• Systemic issues: Liver problems, skin rashes, and blood issues.

The New Discovery: A "Late-Blooming" Problem

For a long time, doctors knew about 9 different genes that could break the "Off Switch" and cause AGS. Usually, these problems show up in babies very early (often before they are 1 year old).

The Twist in this Study:
The researchers found that the PTPN1 gene is a new cause of AGS, but it behaves differently:

1. It shows up later: While other types of AGS hit babies in infancy, PTPN1-related AGS often doesn't show symptoms until the child is 1.75 years old or even older. It's like a security guard who doesn't go rogue until the toddler stage.
2. It's a "Ghost" in the family: In most cases, the child inherited the broken gene from a parent who was perfectly healthy. The parent carried the broken switch but never had the disease. This is called reduced penetrance. It's like a parent carrying a broken key in their pocket that never opens the door, but when they give that key to their child, it somehow jams the lock.

Who Did They Study?

The team looked at a group of 53 children who had all the classic signs of AGS (brain inflammation, developmental regression, specific MRI scans) but had no answer from previous genetic testing.

• The Result: They found that 9 out of 53 (about 17%) of these "unsolved" cases were actually caused by the PTPN1 gene.
• The "All of Us" Check: They also checked a massive database of 245,000 regular people (the "All of Us" biobank). They found 49 people with the same broken gene. None of them had the severe brain disease, but about 21% of them had autoimmune diseases (like lupus or rheumatoid arthritis). This confirms that the broken switch makes you more likely to have immune problems, but it doesn't guarantee you will get the severe brain disease.

The Good News: A Treatment That Works

Since this is an "overactive immune system" problem, the researchers tried a drug called Baricitinib.

• The Analogy: If the immune system is a car speeding out of control, Baricitinib is like a brake pedal. It blocks the signal that tells the immune system to keep attacking.
• The Outcome: When they gave this drug to the children, the "alarm" (measured by specific proteins in the blood) went down in most kids. Their neurological condition either stopped getting worse or actually improved.

Why This Matters

1. Solving Mysteries: If a child has AGS symptoms but started showing them after their first birthday, doctors should now check the PTPN1 gene. It explains about 17% of cases that were previously a mystery.
2. Hope for Treatment: Because we know the mechanism (the immune system is too loud), we know how to treat it (turn down the volume with drugs like Baricitinib).
3. Genetic Counseling: Because the gene can be passed down from healthy parents, families need to understand that carrying the gene doesn't always mean the child will get sick, but it does increase the risk of immune issues.

Summary

This paper found a new "broken switch" (PTPN1) that causes a severe brain disease (AGS). Unlike other versions of this disease, it tends to strike a little later in childhood and often hides in healthy parents. However, because we understand how it works, we can treat it with drugs that calm the immune system down, offering hope to families who previously had no answers.

Technical Summary

1. Problem Statement

Aicardi-Goutières Syndrome (AGS) is a severe, treatable type I interferonopathy caused by the dysregulation of antiviral signaling pathways. While nine genes (TREX1, RNASEH2A/B/C, SAMHD1, ADAR, IFIH1, RNU7-1, LSM11) and two negative regulators (STAT2, USP18) are definitively associated with AGS, a significant portion of patients with clinical, radiological, and biochemical features of AGS remain molecularly undiagnosed.

Recent evidence suggested that PTPN1, a gene encoding the protein tyrosine phosphatase PTP1B (a negative regulator of the interferon pathway), might be associated with pediatric autoinflammatory encephalopathy. However, the association lacked robust replication, and the clinical spectrum, penetrance, and specific phenotypic features of PTPN1-related AGS were not well-characterized. The study aimed to:

• Determine if PTPN1 variants explain a subset of undiagnosed AGS cases.
• Characterize the clinical, radiological, and biochemical phenotype of PTPN1-related disease.
• Assess the penetrance of PTPN1 variants using family segregation and large-scale biobank data.
• Evaluate the therapeutic response to JAK inhibition (Baricitinib).

2. Methodology

The study employed a multi-cohort approach combining deep phenotyping, genomic analysis, and biobank interrogation:

• Cohort Selection:
  • Primary Cohort (MDBP): 53 individuals with a clinical diagnosis of AGS but no molecular diagnosis were recruited from The Children's Hospital of Philadelphia (CHOP). Nine of these were found to harbor PTPN1 variants.
  • Secondary Academic Cohorts: Data from the Amsterdam University Medical Center (UMC) and University College London (UCL) Institute of Neurology were screened, identifying four additional cases.
  • Biobank Analysis: The "All of Us" Research Program database (N=245,394 whole-genome sequences) was queried to identify carriers of ultra-rare PTPN1 predicted loss-of-function (pLOF) or damaging missense variants to assess population prevalence and penetrance.
• Genomic Analysis:
  • Used Exome Sequencing (ES) and Long-Read Genome Sequencing (PacBio).
  • Applied targeted reanalysis workflows using GATK and VEP to filter for ultra-rare pLOF and damaging missense variants (CADD, REVEL, AlphaMissense scores).
  • Segregation analysis was performed via Sanger sequencing in families.
• Clinical & Biochemical Phenotyping:
  • Neurology: Detailed extraction of motor, cognitive, and systemic features; assessment using the AGS Severity Scale (0–11).
  • Radiology: Consensus review of brain MRIs for calcifications, atrophy, white matter changes, and cysts.
  • Interferon Signature: Quantification of Interferon-Stimulated Gene (ISG) scores (specifically IFI44L, IFI27, USP18, IFI6) and CSF neopterin levels in blood and cerebrospinal fluid (CSF).
• Therapeutic Monitoring: Patients treated with Baricitinib (a JAK1/2 inhibitor) were monitored for changes in ISG scores and clinical severity.
• Statistical Analysis: Compared age of onset against a large AGS natural history cohort (N=167) using Mann-Whitney and ANOVA tests.

3. Key Contributions

• Gene Discovery & Validation: Confirmed PTPN1 as a major cause of undiagnosed AGS, identifying 13 new cases (doubling the known cohort).
• Phenotypic Characterization: Defined a distinct clinical profile for PTPN1-related AGS, notably a significantly later age of onset compared to other AGS genotypes.
• Penetrance Estimation: Provided evidence of reduced penetrance, showing that many carriers are asymptomatic or have only mild autoimmune features, complicating genetic counseling.
• Therapeutic Insight: Documented the response of PTPN1-related patients to Baricitinib, showing reduction in interferon signatures and clinical stabilization/improvement.
• Novel Radiological Finding: Identified lenticulostriate calcifications (suggestive of mineralizing angiopathy) in a subset of patients, a feature not previously described in other AGS genotypes.

4. Key Results

A. Genetic Findings

• Prevalence: PTPN1 variants explained ~17% (9/53) of the molecularly unresolved AGS cohort in the MDBP.
• Variant Types: Identified 13 unrelated individuals with ultra-rare heterozygous pLOF (frameshift, nonsense, splice) or damaging missense variants.
• Inheritance: Most variants were inherited from unaffected parents (reduced penetrance). Only 2 cases were de novo. In families where grandparents were tested, variants were found in unaffected carriers.

B. Clinical Phenotype

• Age of Onset: The median age of onset was 1.75 years (IQR 0.67), significantly later than other AGS genotypes (median 0.33 years, p < 0.0001). Only one patient presented before 12 months.
• Neurological Features: Characterized by acute regression of motor and language skills, spasticity, dystonia, ataxia, and irritability.
• Systemic Features: High prevalence of hematological abnormalities, hepatocellular injury (elevated AST/ALT), and lipid abnormalities.
• Biochemical Markers: All 9 definitive cases had elevated CSF neopterin and elevated ISG scores (specifically IFI44L), confirming a type I interferonopathy.

C. Radiological Features

• Common AGS features were present: cerebral atrophy (8/9), white matter hyperintensities (8/9), and putaminal calcifications (6/9).
• Unique Finding: Susceptibility-weighted imaging revealed calcifications along the lenticulostriate vessels in several patients, suggesting a mineralizing angiopathy process.

D. Treatment Response

• All 9 definitive cases were treated with Baricitinib.
• ISG Response: 7/9 patients showed a reduction in ISG scores post-treatment.
• Clinical Response: AGS severity scores remained stable (n=5) or improved (n=4).

E. Penetrance and Biobank Data (All of Us)

• Population Carriers: 49 individuals in the All of Us database carried ultra-rare PTPN1 pLOF or damaging missense variants.
• Phenotype: None of the 49 carriers exhibited AGS features.
• Autoimmunity: However, ~21.6% of carriers had documented autoimmune disorders (e.g., Sjogren's, Lupus, Hashimoto's), compared to ~4.6% in the general US population.
• Penetrance Estimate: The data suggests reduced penetrance, with an estimated penetrance range of 24% to 50% depending on the cohort (clinical vs. biobank).

5. Significance

• Diagnostic Impact: PTPN1 should be included in the diagnostic panel for AGS, particularly for patients with late-onset presentations (after 1 year of age) who are otherwise undiagnosed.
• Clinical Management: The study supports the use of Baricitinib for PTPN1-related AGS, as it effectively lowers interferon signatures and stabilizes clinical status.
• Genetic Counseling: The finding of reduced penetrance and variable expressivity (ranging from severe AGS to isolated autoimmunity or asymptomatic carriage) presents significant challenges for genetic counseling. Unaffected parents carrying the variant may have mild autoimmune conditions, and siblings may be carriers without symptoms.
• Pathophysiology: The results reinforce the role of PTPN1 as a critical negative regulator of the type I interferon pathway. Loss of function leads to unchecked interferon signaling, causing neuroinflammation and autoimmunity.

Conclusion: This study establishes PTPN1 as a common cause of undiagnosed AGS with a distinct, later-onset phenotype and reduced penetrance. It highlights the importance of screening for PTPN1 in unresolved interferonopathy cases and suggests that early JAK inhibition may be a viable therapeutic strategy.